BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

Agenus Inc. , a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25?30, 2025 in Chicago, ...

That trial, the first randomized, double-blind, placebo-controlled study ever conducted in IgG4-RD, confirmed “beyond doubt” that B-cell depletion is an effective treatment strategy for the ...

介绍：Lesigercept莱西格肽‌是一种融合蛋白，由Human FcERI（IgE Fc receptor subunit alpha）的胞外结构域片段与human IgG4的Fc片段融合而成。abinscience产品具有亲和力高，灵敏度高，特异性好，稳定性强等优势。 靶点：FcERI, IgE Fc receptor subunit alpha, FCER1A, Fc-epsilon RI ...

Zenas' lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, which are broadly present across B cell lineage ... that still exist in ...

差异化技术路径的选择往往决定创新药企的命运。派安普利单抗采用IgG1亚型替代常见的IgG4亚型，通过Fc段糖基化改造实现双重优化：一方面保持IgG1更强的抗体依赖性细胞介导的细胞毒作用（ADCC效应），另一方面消除Fc段与FcγR的结合能力，避免杀伤活化的T细胞。

Research suggests there is some relationship between IgG4-RD and autoimmune rheumatic diseases that deserves further exploration. Immunoglobulin G4-related disease (IgG4-RD) is a systemic ...

It’s almost time for the FUT Birthday event in FC 25, one of fans’ favorite Ultimate Team promos in the soccer sim series. As ever, there’ll be a swathe of upgraded cards for players already ...

Journal of Nuclear Medicine March 2025, jnumed.124.268943; DOI: https://doi.org/10.2967/jnumed.124.268943 ...

Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBR ...